Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation

NCT04132102 ·Status: UNKNOWN ·Phase: PHASE4

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

NCT02629523 ·Status: COMPLETED ·Phase: PHASE2

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

NCT02047903 ·Status: COMPLETED

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

NCT01003899 ·Status: COMPLETED ·Phase: PHASE2

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

NCT04206787 ·Status: COMPLETED

Afatinib Expanded Access Program

NCT01649284 ·Status: APPROVED_FOR_MARKETING

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

NCT06062823 ·Status: RECRUITING ·Phase: PHASE2

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

NCT06709859 ·Status: RECRUITING ·Phase: PHASE2

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

NCT05920135 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

NCT02208843 ·Status: COMPLETED ·Phase: PHASE4

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

NCT01746251 ·Status: UNKNOWN ·Phase: PHASE2

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

NCT01932229 ·Status: UNKNOWN ·Phase: PHASE2

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

NCT04640870 ·Status: COMPLETED

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

NCT05267288 ·Status: UNKNOWN ·Phase: PHASE2

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex

NCT02876081 ·Status: WITHDRAWN ·Phase: PHASE2

Afatinib Plus Nimotuzumb for NSCLC

NCT01861223 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

NCT01853826 ·Status: COMPLETED ·Phase: PHASE3

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

NCT01647711 ·Status: COMPLETED ·Phase: PHASE1

Afatinib Genomic Landscape

NCT02491775 ·Status: TERMINATED

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT01480141 ·Status: WITHDRAWN ·Phase: PHASE2

Afatinib in NSCLC With HER2 Mutation

NCT02597946 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

NCT04201756 ·Status: COMPLETED ·Phase: PHASE2

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

NCT06486142 ·Status: RECRUITING ·Phase: PHASE3

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

NCT03486509 ·Status: UNKNOWN ·Phase: PHASE2

Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings

NCT02440854 ·Status: COMPLETED